Skip to content

Comparing Pain Improvement for Intravenous Versus Oral Acetaminophen in Acute Pelvic Pain

Comparing Pain Improvement for Intravenous Versus Oral Acetaminophen in Acute Pelvic Pain: A Randomized, Double-Blind, Double-Dummy Controlled Trial (PIVOTAL Trial)

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07595302
Acronym
PIVOTAL
Enrollment
140
Registered
2026-05-19
Start date
2026-07-30
Completion date
2027-06-30
Last updated
2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Pain

Keywords

pregnancy, acetaminophen, randomized controlled trial

Brief summary

The investigator team proposes a randomized, double-blind, double-dummy comparative effectiveness trial conducted in two urban emergency departments (EDs) in the Bronx, New York. This study is designed to determine the relative efficacy of IV acetaminophen compared to PO acetaminophen in treating pelvic pain. This design focuses on the early onset of action and short-term efficacy, which may better capture potential differences between IV and PO acetaminophen in the acute ED setting.

Detailed description

An estimated 70% of Emergency Department (ED) visits involve pain as a complaint. Although ED practice has shifted away from routine opioid prescribing, uncertainty remains regarding optimal selection among commonly used non-opioid analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen. Medication selection varies by pain etiology, and among patients presenting with musculoskeletal pain, opioids (40.7%), acetaminophen (37.8%), and NSAIDs (22.6%) remain the most frequently administered medications in the ED. Pain in women has been comparatively understudied. Pelvic pain is common among women of childbearing age, and chronic pelvic pain affects up to 24% of women overall. In nonpregnant women, NSAIDs are widely considered first-line therapy for both acute and chronic pelvic pain. In pregnant women and in those attempting to conceive, NSAIDs are typically avoided. Observational studies have associated NSAID use around the time of conception or prior to 20 weeks' gestation with an increased risk of miscarriage, while acetaminophen has not shown a similar association. NSAID exposure in early pregnancy has also been linked to congenital anomalies. Guidelines recommend limiting opioid use during pregnancy and in women of childbearing age. Opioid exposure has been associated with congenital anomalies and with poorer maternal and neonatal outcomes. As a result, opioids are generally avoided as first-line therapy for pelvic pain in patients who are pregnant or may be pregnant. Therefore, it is routine to ascertain pregnancy status prior to administering NSAIDs or opioids to women of childbearing age for an informed decision making discussion. Acetaminophen, in contrast, is generally considered safe in pregnancy and can be administered without delay while awaiting pregnancy testing. Acetaminophen is associated with relatively mild side effects, which may vary by route of administration. Pharmacokinetic studies demonstrate that intravenous acetaminophen achieves higher peak plasma concentrations and faster central nervous system penetration than oral administration. Outside the ED, IV acetaminophen has been associated with faster onset of meaningful pain relief and reduced opioid use in some surgical populations. Whether these pharmacologic advantages translate into clinically meaningful improvements in acute pelvic pain management in the Emergency Department for patients of childbearing potential with pelvic pain is unclear. The investigator team hypothesizes that among women aged 16-50 presenting to the emergency department with pelvic pain, patients receiving intravenous acetaminophen will achieve a greater improvement in the numeric rating scale (NRS) pain score at 30 minutes compared with oral acetaminophen.

Interventions

DRUGAcetaminophen 1000mg PO

Oral Acetaminophen 1000mg

DRUGIV Acetaminophen 1000mg

Intravenous Acetaminophen 1000mg

OTHERIV Placebo

IV placebo administration

Oral placebo administration

Sponsors

Montefiore Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Allocation concealment will be maintained using sequentially numbered medication kits prepared by the research pharmacy. Participants, treating clinicians, research staff, outcome assessors, and investigators will remain blinded to treatment allocation.

Intervention model description

Participants will be randomized in a 1:1 ratio. Randomization will be performed using a computer-generated block randomization scheme, stratified by study site.

Eligibility

Sex/Gender
FEMALE
Age
16 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Female sex at birth * Presentation to the Emergency Department (ED) with pelvic pain * Baseline numeric pain score (NRS) ≥4 * Ability to provide informed consent in English or Spanish

Exclusion criteria

* Receipt of any analgesic medication within 2 hours or acetaminophen within 6 hours * Known allergy or intolerance to acetaminophen

Design outcomes

Primary

MeasureTime frameDescription
Mean Change in Numeric Rating Scale (NRS) scoreFrom baseline to 30 minutes following medication administrationMean Change in NRS score will be assessed at 30 minutes post-treatment. The NRS is a patient self-assessment pain scale that instructs patients to use a facial grimace scale ranging from 0-10 rating to express pain intensity, wherein 0 is "No pain" and 10 is "Worst pain possible," such that higher scores are indicative of greater pain intensity. For purposes of the primary outcome change in NRS score from baseline will be assessed. Results will be summarized by study arm using descriptive statistics.

Secondary

MeasureTime frameDescription
Pain Intensity0-, 5-, 10-, 15-, 30-, 45-, 60- and 120-minutes following medication administrationParticipants will be asked to serially assess their current level of pain intensity as either "Severe," "Moderate," "Mild," or "None." Categorical assessments of pain intensity will be summarized by study arm at each prespecified timepoint.
Time to Clinically Meaningful Reduction in PainWithin 2 hours after medication administrationTime to clinically meaningful pain reduction as assessed by the Numerical Rating Scale (NRS). The NRS is a pain scale that uses a 0-10 rating to measure pain intensity, where 0 is "No pain" and 10 is "Worst pain possible." Clinically meaningful pain reduction will be defined as achieving a reduction in NRS score of ≥1.3 from baseline. Results will be summarized by study arm using basic descriptive statistics.
Use of Rescue MedicationsWithin 2 hours following medication administrationThe number/percentage of patients requiring rescue analgesia of any type within 120 minutes will be summarized by study arm using basic descriptive statistics.
Patient Global Impression of Change (PGI-C) Score30- and 120-minutes following medication administrationEffectiveness of treatment will be evaluated using the PGI-C scale. The PGI-C scale is a 7-point self-reported scale used to assess the patient's perception of change in condition/health status following treatment. Patients will provide a single response as to their self-perception of change in condition/health status on a scale ranging from 1 ("Very much improved") to 7 ("Very much worse)" with 4 representing "No change" as the midpoint. Lower scores are indicative of an improved self-assessment of condition following treatment. Scores will be summarized by study arm using descriptive statistics.
Treatment-Related Adverse Events (TRAEs)Within 2 hours following medication administrationAll treatment-related adverse events occurring within 2 hours of medication administration will be recorded and summarized by study arm.
Emergency Department (ED) DispositionAt 2 hours following medication administrationED disposition will be summarized at 2 hours. Patients will be categorized as either having been admitted, discharged, or status yet to be determined. Categorical data will be summarized by study arm.
Length of Stay (LOS)Less than 24 hours following medication administrationLength of stay will be determined based on the time interval between arrival in the ED and disposition determination. Mean LOS will be summarized by study arm.
Patient SatisfactionAt 2 hours following medication administrationPatient satisfaction will be determined by asking patients whether they would prefer the same medication which was administered during the study if they returned to the ED with the same condition. The number/percentage of patients who prefer the same medication will be summarized by study arm.

Countries

United States

Contacts

CONTACTMustfa Manzur, MD MPH MS
mmanzur@montefiore.org718-920-6674
PRINCIPAL_INVESTIGATOREddie M Irizarry, MD

Montefiore Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026